| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5591762 | BOEHRINGER INGELHEIM | Benzimidazoles useful as angiotensin-11 antagonists |
Jan, 2014
(10 years ago) | |
| US6358986 | BOEHRINGER INGELHEIM | Polymorphs of telmisartan |
Jan, 2020
(4 years ago) | |
Micardis Hct is owned by Boehringer Ingelheim.
Micardis Hct contains Hydrochlorothiazide; Telmisartan.
Micardis Hct has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Micardis Hct are:
- US5591762
- US6358986
Micardis Hct was authorised for market use on 17 November, 2000.
Micardis Hct is available in tablet;oral dosage forms.
Micardis Hct can be used as treatment of hypertension.
The generics of Micardis Hct are possible to be released after 10 January, 2020.
Drugs and Companies using HYDROCHLOROTHIAZIDE; TELMISARTAN ingredient
Market Authorisation Date: 17 November, 2000
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of MICARDIS HCT before it's drug patent expiration?
More Information on Dosage
MICARDIS HCT family patents
